extract: 2024-05-29-nejm-flow-trial-semaglutide-kidney-outcomes

domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md

@@ -30,6 +30,12 @@ For value-based care models and capitated payers, this multi-organ protection cr
 - Nature Medicine: additive benefits with SGLT2 inhibitors
 - First GLP-1 to receive FDA indication for CKD in T2D patients
 
+
+### Additional Evidence (confirm)
+*Source: [[2024-05-29-nejm-flow-trial-semaglutide-kidney-outcomes]] | Added: 2026-03-16*
+
+FLOW trial demonstrated 29% reduction in cardiovascular death (HR 0.71, 95% CI 0.56-0.89) and 18% lower risk of major cardiovascular events in a kidney-focused trial, confirming multi-organ protection extends beyond primary endpoints. Separate Nature Medicine analysis showed additive benefits when combined with SGLT2 inhibitors.
+
 ---
 
 Relevant Notes:

domains/health/semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md

@@ -28,6 +28,12 @@ This is the first dedicated kidney outcomes trial with a GLP-1 receptor agonist,
 - FDA indication expansion to T2D patients with CKD (2024)
 - Dialysis cost benchmark: $90K+/year per patient
 
+
+### Additional Evidence (confirm)
+*Source: [[2024-05-29-nejm-flow-trial-semaglutide-kidney-outcomes]] | Added: 2026-03-16*
+
+FLOW trial (N=3,533, median 3.4 years follow-up) showed 24% reduction in major kidney disease events (HR 0.76, P=0.0003), with annual eGFR slope less steep by 1.16 mL/min/1.73m2 (P<0.001). Trial stopped early for efficacy. FDA subsequently expanded Ozempic indications to include T2D patients with CKD. This is the first dedicated kidney outcomes trial with a GLP-1 receptor agonist.
+
 ---
 
 Relevant Notes:

inbox/archive/2024-05-29-nejm-flow-trial-semaglutide-kidney-outcomes.md

@@ -7,9 +7,13 @@ date: 2024-05-29
 domain: health
 secondary_domains: []
 format: paper
-status: unprocessed
+status: enrichment
 priority: high
 tags: [glp-1, semaglutide, CKD, kidney-disease, FLOW-trial, organ-protection]
+processed_by: vida
+processed_date: 2026-03-16
+enrichments_applied: ["semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md", "glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content
@@ -38,3 +42,13 @@ Additive benefits when used with SGLT2 inhibitors (separate analysis in Nature M
 PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]
 WHY ARCHIVED: Kidney protection is where GLP-1 downstream savings are largest per-patient — dialysis prevention is the economic mechanism most favorable to the VBC cost-saving thesis
 EXTRACTION HINT: Focus on the economic implications of slowed kidney decline for capitated payers, not just the clinical endpoint
+
+
+## Key Facts
+- FLOW trial enrolled 3,533 patients with type 2 diabetes and chronic kidney disease
+- Median follow-up was 3.4 years before early stopping
+- Primary endpoint showed HR 0.76 (P=0.0003) for major kidney disease events
+- Cardiovascular death reduced by 29% (HR 0.71, 95% CI 0.56-0.89)
+- Annual eGFR decline slowed by 1.16 mL/min/1.73m2 with semaglutide
+- FDA expanded Ozempic indications to include CKD in T2D patients post-trial
+- Dialysis costs approximately $90K+/year per patient in the US